TAS-102 Combined With Bevacizumab and Tislelizumab Third-line or Above in the Treatment of Liver Metastasis in Colorectal Cancer
To evaluate the clinical efficacy and safety of TAS-102 combined with bevacizumab and tislelizumab in third-line or above treatment in patients with advanced colorectal adenocarcinoma with liver metastasis.
Immunotherapy|Colorectal Cancer
DRUG: Tislelizumab|DRUG: bevacizumab|DRUG: TAS-102
progression free survival, Time from enrollment to the onset of disease progression or death., up to 24 months
Objective Response Rate (ORR), Objective Response Rate Determine the tumor shrinkage rate, tumor boundary and the adhesion of tumor, every 8 weeks (up to 24 months)
Overall survival (OS), Defined from date of Signing ICF to date of first documentation of death from any cause or censored at the date of the last follow-up., every 3 months (up to 24 months) ]
To evaluate the clinical efficacy and safety of TAS-102 combined with bevacizumab and tislelizumab in third-line or above treatment in patients with advanced colorectal adenocarcinoma with liver metastasis.